BACKGROUND AND PURPOSE:Thromboembolism is one of the most serious complications in coil embolization for intracranial aneurysms, and antiplatelet premedication may reduce this complication. However, interindividual variation exists in the efficacy of CPG. This study sought to elucidate the clinical implications of preinterventional CPG response variability in patients who undergo coil embolization for intracranial aneurysms.

The prasugrel group showed more effective and consistent platelet inhibition. We may omit the antiplatelet response assay with the low-dose prasugrel premedication before the endovascular treatment of patients with unruptured aneurysms. Further study is required to determine whether there is benefit of this strategy regarding clinical outcome.